EasySep™ Direct人CD8+ T细胞分选试剂盒

全血免疫磁珠负选试剂盒

产品号 #19663

直接从全血中免疫磁珠分选CD8+ T细胞

产品优势

  • > 99.9%的红细胞(RBC)去除率,无需密度梯度离心、沉降或裂解
  • 分选获得的细胞纯度高达91%
  • 操作简单、快捷,且无需分离柱
  • 分选得到的细胞不带标记

产品组分包括

  • EasySep™ Direct人CD8+ T细胞分选试剂盒(产品号 #19663)
    • EasySep™ Direct人CD8+ T细胞分选抗体混合物,2 x 2.5 mL
    • EasySep™ Direct RapidSpheres™ 磁珠,4 x 2.5 mL

概述

EasySep™ Direct人CD8+ T细胞分选试剂盒专为从人全血中通过免疫磁珠负选分离CD8+ T细胞而设计。EasySep™ Direct操作流程包括用抗体复合物和磁珠标记人全血中的红细胞、血小板及非他非目标细胞。通过EasySep™磁极将被磁珠标记的细胞与未被标记的目的细胞分离,只需倾倒或者移液即可将目的细胞转移至新试管中。

MAGNET COMPATIBILITY
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• Easy 50 EasySep™ Magnet (Catalog #18002)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
 
SUBTYPE
Cell Isolation Kits
 
CELL TYPE
T Cells, T Cells, CD8+
 
SPECIES
Human
 
SAMPLE SOURCE
Whole Blood
 
SELECTION METHOD
Negative
 
APPLICATION
Cell Isolation
 
BRAND
EasySep
 
AREA OF INTEREST
Immunology

实验数据

Starting with human whole blood from normal healthy donors, the typical CD8+ T cell (CD3+CD8+) content of the non-lysed final isolated fraction is 82.4 ± 4.9% (gated on CD45) or 81.6 ± 4.9% (not gated on CD45).

Figure 1. Typical EasySep™ Direct Human CD8+ T Cell Isolation Profile

Starting with human whole blood from normal healthy donors, the typical CD8+ T cell (CD3+CD8+) content of the non-lysed final isolated fraction is 82.4 ± 4.9% (gated on CD45) or 81.6 ± 4.9% (not gated on CD45). In the example above, the CD8+ T cell (CD3+CD8+) content of the lysed whole blood start sample and non-lysed final isolated fraction is 10.1% and 87.3% (gated on CD45), respectively, or 10.1% and 87.3% (not gated on CD45), respectively. The starting frequency of CD8+ T cells in the non-lysed whole blood start sample is 0.018% (data not shown).

产品说明书及文档

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
19663
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
19663
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
19663
Lot #
All
Language
English

应用领域

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (13)

Frequently Asked Questions

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Publications (1)

Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors. A. Balakrishnan et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 sep

Abstract

PURPOSE The outgrowth of antigen-negative variants is a significant challenge for adoptive therapy with T cells that target a single specificity. Chimeric antigen receptors (CAR) are typically designed with one or two scFvs that impart antigen specificity fused to activation and costimulation domains of T-cell signaling molecules. We designed and evaluated the function of CARs with up to three specificities for overcoming tumor escape using Designed Ankyrin Repeat Proteins (DARPins) rather than scFvs for tumor recognition. EXPERIMENTAL DESIGN A monospecific CAR was designed with a DARPin binder (E01) specific for EGFR and compared with a CAR designed using an anti-EGFR scFv. CAR constructs in which DARPins specific for EGFR, EpCAM, and HER2 were linked together in a single CAR were then designed and optimized to achieve multispecific tumor recognition. The efficacy of CAR-T cells bearing a multispecific DARPin CAR for treating tumors with heterogeneous antigen expression was evaluated in vivo. RESULTS The monospecific anti-EGFR E01 DARPin conferred potent tumor regression against EGFR+ targets that was comparable with an anti-EGFR scFv CAR. Linking three separate DARPins in tandem was feasible and in an optimized format generated a single tumor recognition domain that targeted a mixture of heterogeneous tumor cells, each expressing a single antigen, and displayed synergistic activity when tumor cells expressed more than one target antigen. CONCLUSIONS DARPins can serve as high-affinity recognition motifs for CAR design, and their robust architecture enables linking of multiple binders against different antigens to achieve functional synergy and reduce antigen escape.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。